Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Apr 17, 2026
|
Trevi Therapeutics Prices $150 Million Public Offering
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
STOK
Stoke Therapeutics, Inc.
Lead programs target rare genetic diseases (Dravet syndrome and ADOA), aligning Stoke with the Biotech - Rare Diseases investable theme.
|
$2.13B |
$37.31
+5.57%
|
|
AUPH
Aurinia Pharmaceuticals Inc.
LUPKYNIS (voclosporin) is an immunology/autoimmune therapy, aligning Aurinia's core business with immunology therapeutics.
|
$2.12B |
$16.06
+1.45%
|
|
MESO
Mesoblast Limited
Direct product category: allogeneic mesenchymal lineage cell therapy platform and approved product Ryoncil.
|
$2.11B |
$16.48
+2.42%
|
|
SNDX
Syndax Pharmaceuticals, Inc.
Company focuses on oncology therapeutics, including Revuforj and Niktimvo, placing Syndax in Biotech - Oncology.
|
$2.11B |
$24.20
+1.66%
|
|
AVDL
Avadel Pharmaceuticals plc
LUMRYZ is an oral small molecule therapeutic (sodium oxybate) used to treat narcolepsy; Avadel's core product.
|
$2.10B |
$21.66
+0.09%
|
|
OCUL
Ocular Therapeutix, Inc.
ELUTYX is a proprietary drug-delivery platform central to Ocular Therapeutix's retina-focused pipeline.
|
$2.09B |
$9.82
+10.89%
|
|
ZYME
Zymeworks Inc.
Zymeworks develops oncology therapeutics, including zanidatamab and multiple ADC/MSAT platform programs.
|
$2.08B |
$27.86
+2.41%
|
|
AGIO
Agios Pharmaceuticals, Inc.
Agios's strategic pivot to rare diseases centers on PK activation therapies and a pipeline addressing rare hematologic conditions, aligning with Biotech - Rare Diseases.
|
$2.05B |
$35.13
+0.60%
|
|
AMLX
Amylyx Pharmaceuticals, Inc.
AMX0035 is an oral fixed-dose combination therapy, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$2.02B |
$18.35
+3.50%
|
|
BCRX
BioCryst Pharmaceuticals, Inc.
ORLADEYO is BioCryst's flagship oral small-molecule therapy for hereditary angioedema, a core product.
|
$2.00B |
$9.49
-0.26%
|
|
RXRX
Recursion Pharmaceuticals, Inc.
Collaborations with pharma partners and outsourced discovery work resemble a CRO-type service model.
|
$1.97B |
$3.79
+5.14%
|
|
TRVI
Trevi Therapeutics, Inc.
Trevi Therapeutics develops Haduvio, an oral small molecule therapeutic (nalbuphine ER) for chronic cough.
|
$1.95B |
$15.21
+4.64%
|
|
SION
Sionna Therapeutics, Inc.
Lead candidates are oral small-molecule therapeutics (SION-719, SION-451) in clinical development.
|
$1.94B |
$43.56
-3.71%
|
|
GLPG
Galapagos N.V.
Core product category: CAR-T and other cell therapies (cell therapy platform).
|
$1.93B |
$29.27
+1.42%
|
|
WGS
GeneDx Holdings Corp.
Companion diagnostics partnerships leverage genomic data to identify patients for therapies.
|
$1.91B |
$66.00
+0.89%
|
|
TYRA
Tyra Biosciences, Inc.
TYRA-300 is an oral FGFR3-selective small-molecule inhibitor; TYRA develops oral small-molecule therapeutics.
|
$1.90B |
$35.57
+1.28%
|
|
RAPP
Rapport Therapeutics, Inc. Common Stock
Lead asset RAP-219 is a small molecule AMPAR NAM targeting neuronal ion channels, i.e., ion channel modulators.
|
$1.89B |
$39.91
+0.92%
|
|
ANAB
AnaptysBio, Inc.
Lead programs are monoclonal antibody therapeutics (antibodies such as rosnilimab, ANB033, ANB101).
|
$1.87B |
$67.48
+0.87%
|
|
PHVS
Pharvaris N.V.
Pharvaris' lead program deucrictibant is an oral small-molecule therapeutic targeting Bradykinin B2 receptor for HAE/AAE, fitting the 'Oral Small Molecule Therapeutics' category.
|
$1.86B |
$28.52
-0.90%
|
|
ANIP
ANI Pharmaceuticals, Inc.
ANI's Rare Disease/Brands expansion includes ophthalmic therapies ILUVIEN and YUTIQ acquired via Alimera, marking Ophthalmic Drugs as a direct product category.
|
$1.82B |
$80.97
+3.71%
|
|
DVAX
Dynavax Technologies Corporation
HEPLISAV-B is a hepatitis B vaccine, representing the company's flagship vaccine product.
|
$1.82B |
$15.49
-0.03%
|
|
INVA
Innoviva, Inc.
Zoliflodacin is an oral small-molecule therapeutic in Innoviva's pipeline, representing the IST focus on oral antibiotics.
|
$1.81B |
$24.24
+2.71%
|
|
VCEL
Vericel Corporation
Vericel's core offerings are autologous cell therapies (MACI and Epicel), placing the company in the cell therapy space.
|
$1.80B |
$35.69
+5.69%
|
|
NRIX
Nurix Therapeutics, Inc.
Nurix's pipeline is oncology-focused with BTK/BRAF degraders and IRAK4 degrader in collaboration, aligning with Biotech - Oncology.
|
$1.80B |
$17.50
+4.88%
|
|
TSHA
Taysha Gene Therapies, Inc.
TSHA-102 is an AAV9-based gene therapy product directly developed by Taysha for Rett syndrome.
|
$1.76B |
$6.42
+7.98%
|
|
NUVB
Nuvation Bio Inc.
Core oncology focus with IBTROZI and safusidenib as oncology therapies, fitting Biotech - Oncology.
|
$1.75B |
$5.07
+5.41%
|
|
NTLA
Intellia Therapeutics, Inc.
Direct focus on CRISPR-based in vivo gene therapies (NTLA-2002 and nex-z) and a delivery platform, i.e., core gene-therapy biotech business.
|
$1.73B |
$14.95
+5.54%
|
|
HRMY
Harmony Biosciences Holdings, Inc.
Harmony's WAKIX and pipeline assets target rare neurological diseases, aligning with Biotech - Rare Diseases.
|
$1.73B |
$29.98
+1.92%
|
|
NKTR
Nektar Therapeutics
NKTR's core immunology focus with REZPEG and TNFR2 antibody programs aligns with Immunology Therapeutics.
|
$1.73B |
$84.84
+1.01%
|
|
NBTX
Nanobiotix S.A.
NBTXR3 is Nanobiotix's lead oncology therapy (hafnium oxide nanoparticle) used to enhance radiation therapy, fitting Biotech - Oncology.
|
$1.63B |
$34.07
+4.96%
|
|
PRGO
Perrigo Company plc
Digestive Health OTC products are a significant Perrigo self-care category.
|
$1.62B |
$11.79
+3.24%
|
Showing page 7 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
